 |
Top 10 Drug Discovery startups in USA
Updated: May 07, 2024 |
1
Funding: $1.3B
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
2
Funding: $1.2B
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
3
Funding: $1B
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
4
Funding: $899.9M
Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.
Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.
5
Funding: $772M
Eikon is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
Eikon is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
7
Funding: $693M
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
8
Funding: $665.4M
Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
9
Funding: $546.1M
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
10
Funding: $530.3M
FogPharma creates a new class of medicines that target human disease drivers currently considered undruggable.
FogPharma creates a new class of medicines that target human disease drivers currently considered undruggable.
Ad
Advertise your startup
11
Funding: $487M
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases.
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases.
12
Funding: $460M
Valo Health is a biotech company that is recreating the future of medicine. Valo is using computers to accelerate drug development while reducing the failure rate
Valo Health is a biotech company that is recreating the future of medicine. Valo is using computers to accelerate drug development while reducing the failure rate
13
Funding: $433.5M
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
Dicerna Pharmaceuticals develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases.
14
Funding: $431.1M
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
15
Funding: $407.2M
Synergy is a gastrointestinal-focused biopharmaceutical company committed to science-based innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.
Synergy is a gastrointestinal-focused biopharmaceutical company committed to science-based innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.
16
Funding: $381M
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
17
Funding: $335.4M
Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. Acquired by Gilead Sciences
Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. Acquired by Gilead Sciences
18
Funding: $334.9M
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
19
Funding: $324.3M
Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
20
Funding: $310M
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
21
Funding: $309M
Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.
22
Funding: $294M
Cellarity's platform digitizes the molecular information in cells to elucidate how they behave in health and disease.
Cellarity's platform digitizes the molecular information in cells to elucidate how they behave in health and disease.
23
Funding: $287M
Dewpoint Therapeutics is a biotech company which develop a drug platform that targets biomolecular condensates.
Dewpoint Therapeutics is a biotech company which develop a drug platform that targets biomolecular condensates.
24
Funding: $283.4M
Atea Pharmaceuticals is a biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
Atea Pharmaceuticals is a biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
25
Funding: $269.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
26
Funding: $256.1M
Genesis Therapeutics unifies AI and biotech to accelerate the discovery of new medicines
Genesis Therapeutics unifies AI and biotech to accelerate the discovery of new medicines
27
Funding: $250M
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
28
Funding: $239.3M
Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
29
Funding: $191.4M
Stealth BioTherapeutics is an innovative biopharmaceutical company.
Stealth BioTherapeutics is an innovative biopharmaceutical company.
30
Funding: $176.6M
Atomwise is the creator of AtomNet, the first Deep Learning technology for novel small molecule discovery, characterized by its unprecedented speed, accuracy, and diversity.
Atomwise is the creator of AtomNet, the first Deep Learning technology for novel small molecule discovery, characterized by its unprecedented speed, accuracy, and diversity.
31
Funding: $176.2M
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
32
Funding: $165M
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
33
Funding: $165M
Plexium is a drug development startup that leverages techniques from various physical-science and computational disciplines.
Plexium is a drug development startup that leverages techniques from various physical-science and computational disciplines.
34
Funding: $160M
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.
35
Funding: $157.2M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
36
Funding: $153M
Iambic Therapeutics is built on technologies for predicting protein-ligand structures, generating molecular designs and other drug discovery tasks. Using the technologies, Iambic claims it can accelerate drug discovery, pointing to the two years it took to take its lead project from program launch to IND to make its case.
Iambic Therapeutics is built on technologies for predicting protein-ligand structures, generating molecular designs and other drug discovery tasks. Using the technologies, Iambic claims it can accelerate drug discovery, pointing to the two years it took to take its lead project from program launch to IND to make its case.
37
Funding: $147.6M
Palleon Pharmaceuticals develops drugs that target sugar-sensing molecules on the surfaces of cells. It has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glycoimmune Checkpoint Inhibitors to treat cancer patients.
Palleon Pharmaceuticals develops drugs that target sugar-sensing molecules on the surfaces of cells. It has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glycoimmune Checkpoint Inhibitors to treat cancer patients.
38
Funding: $148M
Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.
Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.
39
Funding: $137.4M
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
40
Funding: $135.5M
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
41
Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
42
Funding: $128.3M
Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services.
Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services.
43
Funding: $115M
Octant Bio is a developer of synthetic technology used to improve health and treat disease.
Octant Bio is a developer of synthetic technology used to improve health and treat disease.
44
Funding: $114.2M
TARIS Biomedical a specialty pharmaceutical company with deep domain expertise in therapeutics and drug-delivery, is focused on local minimally-invasive drug-device convergence products.
TARIS Biomedical a specialty pharmaceutical company with deep domain expertise in therapeutics and drug-delivery, is focused on local minimally-invasive drug-device convergence products.
45
Funding: $100M
Atavistik Bio's drug development platform that focuses on allosteric control mechanisms, which is powered by nature's own evolution, helps to tackle metabolic diseases and cancers
Atavistik Bio's drug development platform that focuses on allosteric control mechanisms, which is powered by nature's own evolution, helps to tackle metabolic diseases and cancers
46
Funding: $99.3M
BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
BigHat Biosciences is a protein therapeutics company that develops an antibody design platform guided by artificial intelligence.
47
Funding: $92M
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.
48
Funding: $67.1M
rdmd empower patients and communities to change the way that drug development happens in rare disease.
rdmd empower patients and communities to change the way that drug development happens in rare disease.
49
Funding: $57M
Moonwalk Biosciences operates a genomic medicine company that aims to provide a new class of precision epigenetic medications.
Moonwalk Biosciences operates a genomic medicine company that aims to provide a new class of precision epigenetic medications.
50
Funding: $54M
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery